ProFoundTx

We’re strengthening our leadership with the appointments of Tom Chittenden as CTO to lead the evolution of the ProFoundry™ Platform's AI, computational, and genetics capabilities & Laurel Ostrom as CHRO to build our organizational foundation and culture: bit.ly/48V52X6

Thrilled to partner with @GSK to advance new #COPD and #IPF therapies, powered by novel proteins discovered by our ProFoundry™ Platform. We look forward to driving innovation in respiratory care. Read more: bit.ly/488VtDA

Addressing complex disease biology calls for innovative solutions. In cardiovascular disease, we're leveraging our ProFoundry™ Platform to reveal a new universe of drug targets and, in collaboration with Novartis, develop transformative therapies: bit.ly/41cpVKj

Understanding industry expectations and mitigating risk are key to the success of bioplatforms. Our CEO, John Lepore, MD, joined @FishburnSimone on the @BioCentury Show to share how we remain resilient in an evolving landscape: bit.ly/4mmmWaL

We’re thrilled to welcome Rebecca Mosher, MD, to ProFound as our new SVP, Oncology Research! A seasoned leader in translational medicine, Rebecca brings deep precision oncology expertise that will support our mission to advance programs powered by the expanded proteome.

Meet David Stone, our new Head of Cardiovascular, Metabolic, and Neuroscience Diseases at ProFound. With 25+ years in genetics, screening & target discovery, David brings the vision and experience to advance transformative therapies for patients. Welcome to the team, David!

We’re thrilled to welcome Tom Chittenden as CTO at ProFound. A pioneer in AI-driven biomedicine, his 25+ years leading data science & platform innovation will drive our efforts to decode the #expandedproteome via the ProFoundry™ Atlas. Learn more: bit.ly/4bDe0aZ

For decades, we believed only ~2% of DNA encodes proteins, but recent research shows ~80% is transcribed into RNA. Our ProFoundry™ Platform is uncovering novel proteins & defining their functions to fuel development of first-in-class medicines. More here: bit.ly/4aV1Kl

We’ve teamed up with @Novartis to tackle #CardiovascularDisease. By combining our ProFoundry™ Platform with their deep expertise, we’re unlocking new biology and accelerating the path to breakthrough therapies. More in this @endpts piece @ByLizC: bit.ly/45J9R5S

We’re proud to partner with @Novartis to discover & develop novel medicines for #cardiovascular disease using our ProFoundry™ Platform. Together, we aim to illuminate new biology & accelerate the path to transformative cardiovascular therapies. Read more: bit.ly/3IhoDXC

Join our CEO, John Lepore, MD, as he takes the stage at #BIO2025 alongside fellow industry leaders to explore how Nobel Prize-winning science can translate into real world therapies to tackle pressing health challenges. Learn more about the panel: bit.ly/4kCJt2d

#NationalDNADay marks the completion of the #HumanGenomeProject. At ProFound, we’re building on that legacy—uncovering novel proteins encoded by previously undefined regions of the genome with vast therapeutic potential. More here: bit.ly/4aV1Klr

Our CEO, John Lepore, is moderating a panel discussion at the @LongwoodLeaders #MiamiCEO meeting where panelists will share expert insights on emerging trends on partnerships and the future of deal-making in biopharma. Details: bit.ly/425tPFL #longwoodhealthcareleaders

What if many ‘non-coding’ RNAs could produce functional proteins? This question fueled development of the ProFoundry™ Platform to rapidly discover and implicate novel proteins in disease. Learn more here: bit.ly/4bDe0aZ

Listen to our CEO, John Lepore, on @SanoGenetics' #TheGeneticsPodcast with @patrick_j_short to learn more about ProFound’s strategy for identifying the most promising drug or drug targets from the #ExpandedProteome. 🎧 bit.ly/3Y06y5s

At ProFound, we’re unlocking the vast potential of the expanded human proteome. Our breakthroughs are reshaping how we view the genome, enabling new possibilities for first-in-class treatments. Learn more about us: bit.ly/3Fse96A

What does 2025 hold for biopharma? We’re most excited about new insights into the #HumanGenome that may drive opportunities for novel drug target identification & validation. Read more from our CEO John Lepore in @PharmaScrip Scrip Asks series: bit.ly/3XbMvRm

On the International Day of Women and Girls in Science, we honor the women shaping the future of healthcare through innovation and dedication. Members of the ProFound team shared advice for aspiring #WomenInScience. Learn more about our team: bit.ly/4bDe0aZ #February11

Scientists at ProFound and beyond are uncovering the hidden universe of 'dark proteins'—overlooked proteins that could play key roles in human disease. These discoveries expand the horizon for #DrugDevelopment, and we’re excited about their potential. Read more in @Nature:

Our CEO, John Lepore, MD, shared the latest on the ProFoundry platform, thoughts on how the company is prioritizing targets that have the potential to become meaningful medicines & plans for the year ahead in a CEO Chat with @FlagshipPioneer: bit.ly/4hwup4a #JPM25